文献速递浆细胞疾病

FlowCT:用于大型免疫表型数据集分析与肿瘤免疫学生物标志物发现

FlowCT for the analysis of large immunophenotypic data sets and biomarker discovery in cancer immunology.
PubMed 文献 · Blood Adv · 2022-01-01

FlowCT 是一个半自动化的开源计算工作空间,整合预处理、归一化、降维、自动聚类和预测建模,用于分析大型流式细胞术数据集。在冒烟型多发性骨髓瘤(SMM)和活动性多发性骨髓瘤(MM)患者中验证,共分析354份样本,识别出预测SMM恶性转化的免疫特征(HR 1.7,P < .001)以及活动性MM的无进展生存(HR 4.09,P < .0001)和总生存(HR 3.12,P = .047)相关指标。

要点

  • FlowCT 可半自动化分析大型流式细胞术数据集,减少人工解读偏差。
  • 在SMM中识别出预测恶性转化的免疫特征(HR 1.7,P < .001)。
  • 在活动性MM中识别出与PFS(HR 4.09)和OS(HR 3.12)相关的T细胞亚群。

核心结论

  • FlowCT 是一种开源计算工具,可对大型免疫监测流式数据进行质控、降维聚类和客观的生物标志物发现。

研究设计与样本

  • 方法学研究,使用 FlowCT 半自动化工作空间分析来自 SMM 和活动性 MM 患者的 354 份骨髓和外周血样本。

主要发现

  • 在150例SMM患者中识别出预测恶性转化的免疫特征(HR 1.7,P < .001)。
  • 在100例活动性MM患者中确定无进展生存(HR 4.09,P < .0001)和总生存(HR 3.12,P = .047)相关指标。
  • 发现关于干细胞记忆T细胞、骨髓与外周血免疫特征一致性以及维持治疗免疫调节作用的新数据。

临床怎么用

  • 研究实验室可实施 FlowCT 进行流式数据质控、高维分析和客观的生物标志物识别。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Large-scale immune monitoring is becoming routinely used in clinical trials to identify determinants of treatment responsiveness, particularly to immunotherapies. Flow cytometry remains one of the most versatile and high throughput approaches for single-cell analysis; however, manual interpretation of multidimensional data poses a challenge when attempting to capture full cellular diversity and provide reproducible results. We present FlowCT, a semi-automated workspace empowered to analyze large data sets. It includes pre-processing, normalization, multiple dimensionality reduction techniques, automated clustering, and predictive modeling tools. As a proof of concept, we used FlowCT to compare the T-cell compartment in bone marrow (BM) with peripheral blood (PB) from patients with smoldering multiple myeloma (SMM), identify minimally invasive immune biomarkers of progression from smoldering to active MM, define prognostic T-cell subsets in the BM of patients with active MM after treatment intensification, and assess the longitudinal effect of maintenance therapy in BM T cells. A total of 354 samples were analyzed and immune signatures predictive of malignant transformation were identified in 150 patients with SMM (hazard ratio [HR], 1.7; P < .001). We also determined progression-free survival (HR, 4.09; P < .0001) and overall survival (HR, 3.12; P = .047) in 100 patients with active MM. New data also emerged about stem cell memory T cells, the concordance between immune profiles in BM and PB, and the immunomodulatory effect of maintenance therapy. FlowCT is a new open-source computational approach that can be readily implemented by research laboratories to perform quality control, analyze high-dimensional data, unveil cellular diversity, and objectively identify biomarkers in large immune monitoring studies. These trials were registered at www.clinicaltrials.gov as #NCT01916252 and #NCT02406144.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Botta C, Maia C, Garcés JJ, et al. FlowCT for the analysis of large immunophenotypic data sets and biomarker discovery in cancer immunology. Blood Adv. 2022. PMID: 34587246. doi:10.1182/bloodadvances.2021005198

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。